Initial data from a pair of clinical trials may revive interest in arthritis drugs as COVID-19 treatments

There is some renewed hope for rheumatoid arthritis drugs like Eli Lilly’s Olumiant and Roche’s Actemra as possible COVID-19 treatments after a series of clinical setbacks this summer seemed to close the door on the category’s potential.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.